FFPE RNA - Seq

This arrangement applies the power of next-generation sequencing (NGS) to the gene expression profile of typical clinical samples. Based on the preparation kit of the TruSeq R RNA access library and the Novogene internal bioinformatics lines, it provides a complete and robust transcriptomic analysis of human RNA isolated from FFPE and other low quality clinical samples.

Secuenciación de ARN de vanguardia para muestras FFPE

Fixation, inclusion and, often, long storage periods of FFPE samples can lead to high RNA degradation, which makes it very difficult to make a reliable and reproducible profile of gene expression with polyA RNA- Seq or RNA-Seq depleted in ribosomes. DIPLOIDE offers FFPE RNA-Seq based on cutting edge capture for FFPE and other low quality samples. This workflow allows researchers to apply the power of next-generation sequencing to the gene expression profile of typical clinical samples. The results of such efforts are increasingly important for the development of new and powerful treatment modalities, such as checkpoint inhibitors and personalized cancer vaccines.

Features

 

  • Complete validation from the isolation of FFPE RNA to the construction of the library and sequencing.

 

  • Unsurpassed data quality with higher Q30 score, higher percentage of clean data, higher mRNA mapping readings and rRNA mapping readings lower than polyA + RNA-seq.

 

  • Extensive experience with hundreds of clinical samples of FFPE analyzed.

 

  • Comprehensive data analysis using widely accepted general software and mature internal pipes. Our professional bioinformatics team offers standard, advanced and customized analysis adapted to the needs of our clients. Raw data and analysis reports can be delivered through hard disks, FTP servers or the DIPLOIDE cloud platform.

New diploide logo letters.png
0

EXPLORE

LEGAL

CONNECT WITH US

  • Black Facebook Icon
  • Black Twitter Icon
  • Black Instagram Icon
  • Black YouTube Icon

Facebook

Twitter

Instagram

YouTube

Linkedin

© 2019 by BIOMED DNA GROUP SAS